Washington Saturday, September 12, 2015, 17:00 Hrs [IST] |
Vanda Pharmaceuticals Inc. (Vanda), a biopharmaceutical company, announced that a favourable Markman ruling has been issued by the United States District Court for the District of Delaware in the patent infringement lawsuit filed by the company against Roxane Laboratories Inc. (Roxane) regarding Roxane’s submission of an Abbreviated New Drug Application to make and sell a generic version of Fanapt, schizophrenia drug.A Markman ruling, also known as a Claim Construction Ruling, is a court ruling in which the judge determines the meaning of key terms from certain disputed patent claims. The Delaware court, which was asked to construe disputed patent claim terms in US patent number 8,586,610 (‘610), rejected Roxane’s proposed construction of all the disputed claim terms. The ‘610 patent is expected to expire in November 2027.Fanapt is an atypical antipsychotic agent indicated for treatment of schizophrenia in adults. In choosing among treatments, prescribers should consider the ability of Fanapt to prolong the QT interval and the use of other drugs first. Prescribers should also consider the need to titrate Fanapt slowly to avoid orthostatic hypotension, which may lead to delayed effectiveness compared to some other drugs that do not require similar titration. |
Vanda gets favorable Markman ruling in Fanapt patent infringement litigation
Related Articles
-
What Is Wrong with Orphan Drug Policies?
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s1098301512041290-mainDownload
-
The face of the patent is not the ‘‘Whole Story’’: determining effective life of a pharmaceutical patent in the United States
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s0172219004000675-mainDownload
-
Evergreening, patent challenges, and effective market life in pharmaceuticals
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s0167629612000057-mainDownload
-
An exploratory analysis of patent fencing in pharmaceuticals: The case of PDE5 inhibitors
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s0048733312002582-mainDownload
-
Evaluating and improving orphan drug regulations in Europe: A Delphi policy study
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s0168851012002461-mainDownload
-
Sanders Asks VA to Break Patents on Gilead and AbbVie Hep C Drugs – Courtesy(Pharmalot)
Pharma Live, , Intellectual Property Rights, 0
The ongoing debate over the cost of prescription drugs took another twist as U.S. Sen. Bernie Sanders (I-VT.) has...
-
A cross-country index of intellectual property rights inpharmaceutical inventions
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s0048733314001164-mainDownload
-
Novartis Patent Application Rejected in India!
Pharma Live, , Intellectual Property Rights, 0
NOVARTIS spent nearly 15 years seeking a patent in India for Glivec, a medicine for chronic myeloid leukemia. That...
![](https://interactivepharm.com/wp-content/uploads/2022/08/Show-your.jpg)